Publications
Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, Vasan N, Cai Y, Bielski CM, Donoghue MTA, Jonsson P, Penson A, Shen R, Pareja F, Kundra R, Middha S, Cheng ML, Zehir A, Kandoth C, Patel R, Huberman K, Smyth LM, Jhaveri K, Modi S, Traina TA, Dang C, Zhang W, Weigelt B, Li BT, Ladanyi M, Hyman DM, Schultz N, Robson ME, Hudis C, Brogi E, Viale A, Norton L, Dickler MN, Berger MF, Iacobuzio-Donahue CA, Chandarlapaty S, Scaltriti M, Reis-Filho JS, Solit DB, Taylor BS, Baselga J. The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. Cancer cell. 2018. PMID: 30205045
Saad F, Cella D, Basch E, Hadaschik BA, Mainwaring PN, Oudard S, Graff JN, McQuarrie K, Li S, Hudgens S, Lawson J, Lopez-Gitlitz A, Yu MK, Smith MR, Small EJ. Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial. The Lancet. Oncology. 2018. PMID: 30213449
Su Y, Liu Y, Behrens CR, Bidlingmaier S, Lee NK, Aggarwal R, Sherbenou DW, Burlingame AL, Hann BC, Simko JP, Premasekharan G, Paris PL, Shuman MA, Seo Y, Small EJ, Liu B. Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer. JCI insight. 2018. PMID: 30185663
Cheng ML, Oxnard GR. Does TMB Impact the Effectiveness of TKIs in EGFR-Mutant NSCLC? Clinical cancer research : an official journal of the American Association for Cancer Research. 2018. PMID: 30190372
Rubenstein JL. Can rituximab unlock the innate potential of checkpoint blockade in the CNS? Leukemia & lymphoma. 2018. PMID: 30188237
Muhsen IN, Aljurf M, Wingard JR, Poland GA, Komanduri KV, Whitaker JA, Hashmi SK. Vaccinating donors for hematopoietic cell transplantation: A systematic review and future perspectives. Vaccine. 2018. PMID: 30195488
Leleu X, Martin TG, Einsele H, Lyons RM, Durie BGM, Iskander KS, Ailawadhi S. Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma. Clinical lymphoma, myeloma & leukemia. 2018. PMID: 30287200
Magbanua MJM, Rugo HS, Hauranieh L, Roy R, Scott JH, Lee JC, Hsiao F, Sosa EV, Van't Veer L, Esserman LJ, Park JW. Genomic and expression profiling reveal molecular heterogeneity of disseminated tumor cells in bone marrow of early breast cancer. NPJ breast cancer. 2018. PMID: 30211312
Sannino S, Guerriero CJ, Sabnis AJ, Stolz DB, Wallace CT, Wipf P, Watkins SC, Bivona TG, Brodsky JL. Compensatory increases of select proteostasis networks after Hsp70 inhibition in cancer cells. Journal of cell science. 2018. PMID: 30131440
Li H, Xu Y, Zhao F, Song G, Rugo HS, Zhang Y, Yang L, Liu X, Shao B, Yang L, Liu Y, Ran R, Zhang R, Guan Y, Chang L, Yi X. Plasma PIK3CA ctDNA specific mutation detected by next generation sequencing is associated with clinical outcome in advanced breast cancer. American journal of cancer research. 2018. PMID: 30323979
Ettl J, Quek RGW, Lee KH, Rugo HS, Hurvitz S, Gonçalves A, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Markova D, Bhattacharyya H, Hannah AL, Eiermann W, Blum JL, Litton JK. Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Annals of oncology : official journal of the European Society for Medical Oncology. 2018. PMID: 30124753
Dhruva A, Atreya CE, Chao MT. Applying New Models of Care to Meet Patient Needs in Integrative Oncology. Journal of alternative and complementary medicine (New York, N.Y.). 2018. PMID: 30247958
Kardosh A, Lichtensztajn DY, Gubens MA, Kunz PL, Fisher GA, Clarke CA. Long-Term Survivors of Pancreatic Cancer: A California Population-Based Study. Pancreas. 2018. PMID: 30074526
Cheng ML, Berger MF, Hyman DM, Solit DB. Clinical tumour sequencing for precision oncology: time for a universal strategy. Nature reviews. Cancer. 2018. PMID: 30030494
Ashworth A, Lord CJ. Synthetic lethal therapies for cancer: what's next after PARP inhibitors? Nature reviews. Clinical oncology. 2018. PMID: 29955114
Tempero M. Getting What You Pay For: Finding Value in Cancer Care. Journal of the National Comprehensive Cancer Network : JNCCN. 2018. PMID: 30181413
Van Loon K, Mwachiro MM, Abnet CC, Akoko L, Assefa M, Burgert SL, Chasimpha S, Dzamalala C, Fleischer DE, Gopal S, Iyer PG, Kaimila B, Kayamba V, Kelly P, Leon ME, Mathew CG, Menya D, Middleton D, Mlombe Y, Mmbaga BT, Mmbaga E, Mulima G, Murphy G, Mushi B, Mwanga A, Mwasamwaja A, Parker MI, Pritchett N, Schüz J, Topazian MD, White RE, McCormack V, Dawsey SM. The African Esophageal Cancer Consortium: A Call to Action. Journal of global oncology. 2018. PMID: 30241229
Bugaj LJ, Sabnis AJ, Mitchell A, Garbarino JE, Toettcher JE, Bivona TG, Lim WA. Cancer mutations and targeted drugs can disrupt dynamic signal encoding by the Ras-Erk pathway. Science (New York, N.Y.). 2018. PMID: 30166458
Ho WJ, Yarchoan M, Hopkins A, Mehra R, Grossman S, Kang H. Association between pretreatment lymphocyte count and response to PD1 inhibitors in head and neck squamous cell carcinomas. Journal for immunotherapy of cancer. 2018. PMID: 30170629
Rabow MW, McGowan M, Small R, Keyssar R, Rugo HS. Advance Care Planning in Community: An Evaluation of a Pilot 2-Session, Nurse-Led Workshop. The American journal of hospice & palliative care. 2018. PMID: 30153741